Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that…
Verona Pharma, a respiratory disease-focused drugmaker, said on Wednesday that the first patients have been dosed in a Phase 2b clinical trial testing RPL554 as a maintenance treatment for chronic obstructive pulmonary disease (COPD). Verona Pharma expects to report top-line data from this trial in the second half of 2018.
The growing incidence of more Western lifestyle diseases such as cardiovascular disease (CVD), cancer, diabetes and respiratory disease, in addition to infectious and parasitic illness, will present the pharmaceutical industry in Africa with a business opportunity of $40.8 billion in 2019.
Vectura Group has reached a royalty cap on net sales of £9 million from selling GSK’s respiratory Ellipta products in 2016.